Sinco Pharmaceuticals Holdings Limited (06833.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	4.4B	2.1B	2.8B	2.5B	2.3B
Cost of Revenue	3.9B	1.9B	2.5B	2.2B	2.0B
Gross Profit	471.2M	222.1M	299.9M	323.3M	305.9M
Operating Expenses
R&D Expense	41.7M	2.7M	19.0M	8.3M	11.3M
SG&A Expense	313.2M	147.4M	189.9M	202.6M	198.4M
General & Admin Expense	145.7M	81.8M	126.0M	108.9M	81.4M
Selling & Marketing Expense	85.0M	57.6M	63.9M	93.7M	117.0M
Other Expenses	—	—	(3.9M)	4.2M	6.2M
Total Operating Expenses	354.9M	150.1M	205.0M	215.1M	215.9M
Cost and Expenses	4.3B	2.0B	2.7B	2.4B	2.2B
Operating Income (EBIT)	116.4M	72.0M	94.9M	108.2M	90.0M
Non-Operating
Interest Income	7.0M	3.9M	6.1M	1.3M	2.4M
Interest Expense	42.1M	33.1M	12.5M	9.8M	13.8M
Net Interest Income	(38.3M)	(29.1M)	(6.4M)	(8.5M)	(11.4M)
Other Non-Op Income/Expense	(7.0M)	(23.7M)	4.0M	(8.3M)	9.3M
Non-Operating Income (excl Interest)	(41.7M)	(2.7M)	(19.0M)	(1.5M)	(11.3M)
EBT (Pre-Tax Income)	109.4M	48.3M	98.9M	99.9M	99.3M
Income Tax Expense	36.4M	13.4M	56.9M	57.5M	29.8M
Bottom Line
Net Income	73.0M	34.9M	42.0M	42.4M	69.5M
Earnings from Cont. Ops	73.0M	34.9M	42.0M	42.4M	69.5M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	73.0M	34.9M	42.0M	42.4M	69.5M
Per Share
Basic EPS	HK$0.04	HK$0.02	HK$0.02	HK$0.02	HK$0.03
Diluted EPS	HK$0.04	HK$0.02	HK$0.02	HK$0.02	HK$0.03
Revenue Per Share	HK$2.17	HK$1.03	HK$1.39	HK$1.25	HK$1.12
Shares
Basic Shares Outstanding	2.0B	2.0B	2.0B	2.0B	2.0B
Diluted Shares Outstanding	2.0B	2.0B	2.0B	2.0B	2.0B
Profitability Metrics
EBITDA	204.4M	93.5M	132.6M	126.0M	109.0M
D&A	46.3M	18.8M	18.7M	16.3M	7.8M
EBIT	158.1M	74.7M	113.9M	109.7M	101.2M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026